Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Brand Name :
Actiq, Onsolis, Subsys, Fentora, Abstral
Synonyms :
fentanyl transmucosal
Class :
Opioid Analgesics, Anilidopiperidine
Dosage Forms & StrengthsÂ
Schedule II troche/lozenge (Actiq)Â
1600mcgÂ
1200mcgÂ
800mcgÂ
600mcgÂ
400mcgÂ
200mcgÂ
Schedule II tablet, sublingual (Abstral)Â
800mcgÂ
600mcgÂ
400mcgÂ
300mcgÂ
200mcgÂ
100mcgÂ
Schedule II buccal tablet (Fentora)Â
800mcgÂ
600mcgÂ
400mcgÂ
200mcgÂ
100mcgÂ
Schedule II soluble film (Onsolis)Â
1200mcgÂ
800mcgÂ
600mcgÂ
400mcgÂ
200mcgÂ
Schedule II sublingual spray (Subsys)Â
800mcg/sprayÂ
600mcg/sprayÂ
400mcg/sprayÂ
200mcg/sprayÂ
100mcg/sprayÂ
In the patients receiving opioid analgesics (60 mg or more morphine per day or 50 mcg fentanyl transdermally every hour)
Titrate the medication to a tolerable and effective dose
Abstral- Initially, 100 mcg sublingually; give the next dose not before 4 hours
Actiq- Dissolve 200 mcg in the mouth for at least 15 minutes as required
Titrate it upto 1600 mcg
Fentora- Initially 100 mcg; give the dose again 30 minutes later
Keep the buccal tablet between the cheek & gum until it dissolves
Subsys- Initially, 100 mcg sublingually and titrate the dose
Safety and efficacy are not seen in pediatricsÂ
Refer to the adult dosingÂ
Actions and Spectrum:Â
Actions:Â
fentanyl transmucosal formulations provide potent analgesic (pain-relieving) effects by binding to opioid receptors of the CNS. They help to alleviate severe pain, including breakthrough pain episodes that occur despite ongoing opioid therapy.Â
fentanyl transmucosal medications are designed to provide a rapid onset of pain relief. When used as directed, they can deliver fentanyl directly into the bloodstream via mucous membranes of the mouth or buccal cavity, leading to a relatively quick onset of action.Â
Spectrum:Â
The spectrum of fentanyl transmucosal refers to its effectiveness and potential uses. fentanyl transmucosal products are indicated explicitly for breakthrough cancer pain in patients tolerant to opioid therapy. Breakthrough pain is a sudden and severe flare-up that occurs despite ongoing opioid treatment for chronic cancer pain. fentanyl transmucosal formulations are intended to provide additional analgesia during these episodes of breakthrough pain.Â
Frequency definedÂ
>10%Â
AstheniaÂ
ConfusionÂ
ConstipationÂ
Dry mouthÂ
NauseaÂ
SomnolenceÂ
SweatingÂ
VomitingÂ
1-10%Â
AnorexiaÂ
Abdominal painÂ
DiarrheaÂ
EuphoriaÂ
AnxietyÂ
ApneaÂ
DepressionÂ
FatigueÂ
DizzinessÂ
DyspepsiaÂ
DyspneaÂ
HemoptysisÂ
HypoventilationÂ
HallucinationsÂ
HeadacheÂ
PruritusÂ
Urinary retentionÂ
Influenza-like symptomsÂ
NervousnessÂ
PharyngitisÂ
Upper respiratory tract infectionÂ
Frequency Not DefinedÂ
AmnesiaÂ
AgitationÂ
Abnormal coordinationÂ
ThinkingÂ
GaitÂ
DreamsÂ
Application site reactionÂ
FlatulenceÂ
Micturition disorderÂ
Back painÂ
BronchitisÂ
FeverÂ
Mucosal inflammationÂ
HiccupsÂ
Accidental injuryÂ
Rhinitis, sinusitisÂ
Speech disorderÂ
Paranoid reactionÂ
ParesthesiaÂ
RashÂ
SyncopeÂ
ST-segment elevationÂ
Ventricular tachycardiaÂ
TremorÂ
BradycardiaÂ
QT-interval prolongationÂ
Severe cardiac arrhythmiasÂ
MIÂ
Angina pectorisÂ
Visual disturbancesÂ
Mental cloudingÂ
Respiratory/circulatory depressionÂ
Respiratory arrestÂ
ShockÂ
Black Box Warning:Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
Category CÂ
Breastfeeding warnings:Â Â
The drug is excreted in breast milk. Â
Use the during lactation only when no other substitute is available. Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
fentanyl, the active ingredient in fentanyl transmucosal formulations, is a potent opioid analgesic. It acts primarily by binding to the mu-opioid receptors in the central nervous system, exerting agonist effects. By activating these receptors, fentanyl inhibits the transmission of pain signals, resulting in analgesia.Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
The bioavailability of onsolis is 71%Â
The duration of action is 1-2 hoursÂ
DistributionÂ
The peak plasma concentration is achieved at 0.5-4 hoursÂ
MetabolismÂ
CYP3A4 extensively metabolizes the drug. Inactive nor fentanyl metabolites are formedÂ
Elimination and ExcretionÂ
The half-life is 1.5-6 hoursÂ
The drug is excreted in feces and urine.Â
Administration:Â
fentanyl transmucosal formulations are typically administered using specific delivery systems designed for mucosal absorption. The most common administration forms include fentanyl buccal tablets (also known as fentanyl buccal soluble film) and fentanyl sublingual tablets (also known as fentanyl sublingual spray).Â
Patient information leafletÂ
Generic Name: fentanyl transmucosalÂ
Pronounced: fen-tah-nyl traans-myuh-cosalÂ
Why do we use fentanyl transmucosal?Â
fentanyl transmucosal formulations are designed to provide rapid relief during cancer breakthrough pain episodes.Â